

Author Index Volume 1 (2012)

The issue number is given in front of the pagination

- Alam, I., and G. Pawelec, Aging, nutrition and immunity – their relationship and interaction (3,4) 151–165
- Amit, T., see Weinreb, O. (1) 27–39
- Bennetau-Pelissero, C., see Chanut, A. (2) 113–123
- Bérard, A.M., see Chanut, A. (2) 113–123
- Calhau, C., see Faria, A. (2) 89–97
- Carey, A.N., S.M. Poulouse and B. Shukitt-Hale, The beneficial effects of tree nuts on the aging brain (1) 55–67
- Chanet, A., P. Wizinska, S. Polakof, A. Mazur, C. Bennetau-Pelissero, C. Morand, A.M. Bérard and D. Milenkovic, Naringin at a nutritional dose modulates expression of genes related to lipid metabolism and inflammation in liver of mice fed a high-fat diet (2) 113–123
- Dye, L., see Lamport, D.J. (1) 5–25
- Faria, A., N. Mateus and C. Calhau, Flavonoid transport across blood-brain barrier: Implication for their direct neuroprotective actions (2) 89–97
- Fouquet, E., see Guéroux, M. (3,4) 201–206
- Gibson, G.R., see Toward, R.E. (3,4) 167–180
- Giovannelli, L., Beneficial effects of olive oil phenols on the aging process: Experimental evidence and possible mechanisms of action (3,4) 207–223
- Guéroux, M., M. Laguerre, M. Szlosek-Pinaud, E. Fouquet and I. Pianet, Polyphenols and Alzheimer's Disease: Tau/polyphenol interactions investigated by NMR and molecular modeling (3,4) 201–206
- Han, J., see Sasaki, K. (2) 141–150
- Isoda, Hiroko, see Sasaki, K. (2) 141–150
- Jackson, K.G., and J.A. Lovegrove, Impact of probiotics, prebiotics and synbiotics on lipid metabolism in humans (3,4) 181–200
- Laguerre, M., see Guéroux, M. (3,4) 201–206
- Lamport, D.J., L. Dye, J.D. Wightman and C.L. Lawton, The effects of flavonoid and other polyphenol consumption on cognitive performance: A systematic research review of human experimental and epidemiological studies (1) 5–25
- Lawton, C.L., see Lamport, D.J. (1) 5–25
- Lockyer, S., P. Yaqoob, J.P.E. Spencer and I. Rowland, Olive leaf phenolics and cardiovascular risk reduction: Physiological effects and mechanisms of action (2) 125–140
- Lovegrove, J.A., see Jackson, K.G. (3,4) 181–200
- Mateus, N., see Faria, A. (2) 89–97
- Mazur, A., see Chanet, A. (2) 113–123
- Milenkovic, D., see Chanet, A. (2) 113–123
- Minihane, A.M., see Vauzour, D. (1) 41–53
- Morand, C., see Chanet, A. (2) 113–123
- Pawelec, G., see Alam, I. (3,4) 151–165
- Pianet, I., see Guéroux, M. (3,4) 201–206
- Polakof, S., see Chanet, A. (2) 113–123
- Poulouse, S.M., see Carey, A.N. (1) 55–67
- Rauter, A.P., see Roseiro, L.B. (2) 99–111
- Roseiro, L.B., A.P. Rauter and M.L.M. Serralheiro, Polyphenols as acetylcholinesterase inhibitors: Structural specificity and impact on human disease (2) 99–111
- Rowland, I., see Lockyer, S. (2) 125–140
- Sasaki, K., J. Han, H. Shigemori and Hiroko Isoda, Caffeoylquinic acid induces ATP production and energy metabolism in human neurotypic SH-SY5Y cells (2) 141–150
- Saunders, C., and J.P.E. Spencer, Metabolic and immune risk factors for dementia and their modification by flavonoids: New targets for the prevention of cognitive impairment? (1) 69–88
- Serralheiro, M.L.M., see Roseiro, L.B. (2) 99–111
- Shigemori, H., see Sasaki, K. (2) 141–150
- Shukitt-Hale, B., see Carey, A.N. (1) 55–67
- Spencer, J.P.E., see Saunders, C. (1) 69–88

- Spencer, J.P.E., see Lockyer, S. (2) 125–140
Szlosek-Pinaud, M., see Guéroux, M. (3,4) 201–206
- Toward, R.E., G.E. Walton and G.R. Gibson,
Immunosenescence and the gut microbiota: The
role of probiotics and prebiotics (3,4) 167–180
- Vauzour, D., and A.M. Minihane, Neuroinflammation
and the *APOε* genotype: Implications for
Alzheimer's disease and modulation by dietary
flavonoids and n-3 polyunsaturated fatty acids (1)
41–53
- Walton, G.E., see Toward, R.E. (3,4) 167–180
Weinreb, O., T. Amit and M.B.H. Youdim, Targeting
dysregulation of brain iron homeostasis in ageing
(1) 27–39
Wightman, J.D., see Lamport, D.J. (1) 5–25
Wizinska, P., see Chanet, A. (2) 113–123
- Yaqoob, P., see Lockyer, S. (2) 125–140
Youdim, M.B.H., see Weinreb, O. (1) 27–39